Publications by authors named "Bin-Shen Ou-Yang"
Newly diagnosed follicular lymphoma (FL) patients usually received first-line rituximab-based immunochemotherapy (R-chemo). Recently, rituximab plus lenalidomide (R2) emerged as an alternative chemo-free immunotherapy. We performed a comparative analysis of positron emission tomography/computed tomography (PET/CT) in FL undergoing R-chemo or R2.
View Article and Find Full Text PDFArticle Synopsis
- * A study analyzing 128 biopsy samples identified three distinct subtypes of NKTCL, each with unique characteristics, including cell origin and how they respond to treatments.
- * The results highlight the molecular mechanisms of EBV-related NKTCL and could lead to improved clinical treatment strategies for patients.
Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cells represent a novel immunotherapy and are highly effective in treating relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL). How tumor microenvironment influences clinical response to CAR T therapy remains of great interest.
Patients And Methods: A phase I, first-in-human, dose-escalation study of anti-CD19 JWCAR029 was conducted in refractory B-NHL (NCT03355859) and 10 patients received CAR T cells at an escalating dose of 2.
Article Synopsis
- Diffuse large B-cell lymphoma (DLBCL) is a type of cancer that can show up in different ways and has different chances of getting better.
- The study looked at how problems with the liver before treatment affect patient outcomes in DLBCL, finding that liver issues were linked to worse results but were not caused by hepatitis B or cancer spreading to the liver.
- Researchers created a new scoring system called liver-IPI that includes liver health as an important factor, and it helps predict survival chances better than older systems.